North Star Investment Management Corp. Has $8.36 Million Holdings in Pfizer Inc. (NYSE:PFE)

North Star Investment Management Corp. cut its position in shares of Pfizer Inc. (NYSE:PFE) by 1.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 289,007 shares of the biopharmaceutical company’s stock after selling 3,118 shares during the quarter. North Star Investment Management Corp.’s holdings in Pfizer were worth $8,364,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Olistico Wealth LLC acquired a new position in shares of Pfizer during the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer in the second quarter valued at approximately $29,000. Quarry LP acquired a new stake in shares of Pfizer in the second quarter valued at approximately $31,000. Financial Connections Group Inc. bought a new position in shares of Pfizer during the 2nd quarter worth approximately $34,000. Finally, ESL Trust Services LLC acquired a new position in shares of Pfizer during the 1st quarter worth approximately $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Buying and Selling

In related news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target on the stock. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $33.58.

Pfizer Price Performance

Shares of PFE stock traded down $0.01 on Tuesday, reaching $27.75. The company had a trading volume of 6,934,879 shares, compared to its average volume of 37,141,242. The stock has a market capitalization of $157.25 billion, a PE ratio of 37.51, a price-to-earnings-growth ratio of 0.89 and a beta of 0.67. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The business’s 50-day moving average is $29.01 and its 200 day moving average is $28.63. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the previous year, the company posted ($0.17) EPS. Pfizer’s quarterly revenue was up 31.2% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.05%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.